iiinova — where your digital self keeps evolving

City Therapeutics @citytx.bsky.social · 11/08/2026

We're thrilled to welcome Keith Regnante as CFO and Mary Beth DeLena as CLO to City Therapeutics. www.citytx.com/news/city-th...

020

City Therapeutics @citytx.bsky.social · 08/06/2026

We're excited to announce the closing of our $99.5M Series B financing to advance our next-gen RNAi therapeutics engineering platform & pipeline, including our ongoing Phase 1 clinical trial of CITY-FXI & two additional programs progressing toward the clinic. www.citytx.com/news/city-th...

031

City Therapeutics @citytx.bsky.social · 14/05/2026

Our CEO Andy Orth will join fellow BioSpace NextGen Class of 2026 leaders, Eric Green (Trace Neuroscience) & Mohit Trikha (Kivu Bioscience) for a webinar hosted by Annalee Armstrong on what it takes to survive & thrive in today’s biotech market. www.biospace.com/events/regis...

010

City Therapeutics @citytx.bsky.social · 08/05/2026

Excited to see Founder & Exec Chair @jmaraganore.bsky.social take the stage @ @FierceBiotech Week on the next chapter of RNAi. John helped transform RNAi from hypothesis to established modality & at City, we're harnessing that expertise to push it further. www.fiercebiotechweek.com/event/fierce...

000

City Therapeutics @citytx.bsky.social · 06/05/2026

We’re presenting new preclinical data at #ARVO2026 on our investigational RNAi therapy, CITY-RBP4, for #StargardtDisease. Data show potent, durable RBP4 silencing and reduced toxic retinoids. Learn more: www.businesswire.com/news/home/20...

000

City Therapeutics @citytx.bsky.social · 02/04/2026

Great to be part of the conversation at MassBio’s State of Possible, where our CEO Andy Orth joined the Biotech CEOs on the Frontlines panel. Andy shared our work philosophy, WFC (Work from City), & that for us, being together fuels creativity, deepens connection & accelerates scientific discovery.

000

City Therapeutics @citytx.bsky.social · 27/03/2026

Exciting week at Keystone Symposia! We shared new science from our differentiated RNAi platform, from peptide-enabled siRNA delivery to the CNS & eye, to cityRNAs as novel RNAi agents expanding RNA-based precision medicine.

000

City Therapeutics @citytx.bsky.social · 11/02/2026

On #IDWGS, we’re proud to recognize the women at City whose curiosity, expertise, and dedication help drive our science forward. We asked a few Citizens what it means to be a woman in this field, and their perspectives speak for themselves below.

010

City Therapeutics @citytx.bsky.social · 27/01/2026

City Therapeutics is #hiring across discovery, nonclinical, and clinical development. If you bring courage to tackle complex science, innovation to push boundaries, and the tempo to build with purpose, plus a collaborative “yes” mindset. Apply: www.citytx.com/home#culture

011

City Therapeutics @citytx.bsky.social · 07/01/2026

Proud moment for City: We’ve been named to BioSpace’s NextGen Class of 2026, recognizing top up-and-coming #lifescience companies in North America. We’re grateful for the recognition and proud of our team pushing innovative #RNAi therapeutics. www.biospace.com/nextgen

010

City Therapeutics @citytx.bsky.social · 23/12/2025

Festive moments at City this week, from a Yankee Swap to celebrating our NEVY Award win in City tees, plus spotting one all the way in Australia. We also gave back with @lifesciencecares.bsky.social and Hyde Square Task Force. We’re growing and hiring: www.citytx.com/home#culture

010

City Therapeutics @citytx.bsky.social · 22/12/2025

Congrats to City founder @jmaraganore.bsky.social on receiving the Lifetime Achievement Award by @BosBizJournal’s Innovators in Healthcare 2026! His commitment to translating innovation into patient impact is foundational to our efforts in RNAi therapeutics. www.bizjournals.com/boston/news/...

000

City Therapeutics @citytx.bsky.social · 12/12/2025

We’re excited to share that City Therapeutics won Emerging Company of the Year at New England VC’s 13th Annual #NEVYs25! It’s a meaningful moment for our team as we continue advancing RNAi therapeutics with purpose, care, and recognized momentum.

000

City Therapeutics @citytx.bsky.social · 10/11/2025

Excited to announce the submission of our CTA to the @mhragovuk.bsky.social to initiate a Phase 1 study of CITY-FXI, an investigational RNAi therapeutic targeting Factor XI w/ the potential to safely & effectively prevent blood clots without increasing bleeding risk. www.citytx.com/news/city-th...

012

City Therapeutics @citytx.bsky.social · 29/10/2025

Honored to be named by LinkedIn as a Top 10 #LinkedInTopStartups of Boston in 2025! In the heart of Kendall Square, we’re building a place where careers & cutting-edge RNAi science can thrive. www.linkedin.com/pulse/linked...

011

City Therapeutics @citytx.bsky.social · 08/10/2025

One year strong, from growing our team to building partnerships, our focus is unwavering to reshape the future of RNAi medicines. Here's to what's next!

010

City Therapeutics @citytx.bsky.social · 07/10/2025

Check out City's Executive Chair, @jmaraganore.bsky.social presenting at Fierce Biotech Week 2025 this week, where he'll offer insights from his past and reflect on the evolving landscape of RNAi! www.fiercebiotechweek.com/event/fierce...

fiercebiotechweek.com

Featured Presentation: Building Alnylam and the Importance of Being Unreasonable | Fierce Biotech Week

020

City Therapeutics @citytx.bsky.social · 27/05/2025

Exciting news from City! We’ve partnered with Biogen to develop select novel RNAi-based therapies leveraging our next-generation RNAi engineering technologies. Learn more: www.globenewswire.com/news-release...

012

City Therapeutics @citytx.bsky.social · 17/04/2025

Excited to welcome Baisong Mei, M.D., Ph.D., as CMO, Anna O’Driscoll as CHRO, and Sara Nochur, Ph.D., as an independent board member! Their expertise in life sciences will help drive our next phase of growth. Learn more below and at: www.businesswire.com/news/home/20...

021